Literature DB >> 6997386

Mechanism of B cell lymphoma immunotherapy with passive xenogeneic anti-idiotype serum.

L L Lanier, G F Babcock, R B Raybourne, L W Arnold, N L Warner, G Haughton.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6997386

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


× No keyword cloud information.
  11 in total

1.  Factors influencing antibody-mediated cytotoxicity during the immunotherapy of Rauscher-virus-induced myeloid leukemic cells.

Authors:  D Berends; T H van der Kwast; N J de Both; P G Mulder
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 2.  Treatment of lymphoid tumors with anti-idiotype antibodies.

Authors:  G T Stevenson; F K Stevenson
Journal:  Springer Semin Immunopathol       Date:  1983

3.  Biological effects of antibodies to lymphocyte surface receptors.

Authors:  J W Goding
Journal:  Springer Semin Immunopathol       Date:  1982

4.  Chimeric univalent antibodies for treating lymphoid malignancies.

Authors:  G T Stevenson; V M Cole; J Summerton; H F Watts
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

Review 5.  Three major uncertainties in the antibody therapy of cancer.

Authors:  George T Stevenson
Journal:  Haematologica       Date:  2014-10       Impact factor: 9.941

6.  The assessment of anti-idiopathic antibodies as effective immunoregulatory probes in vivo.

Authors:  J C Olson; C R Wagner; G A Leslie
Journal:  Clin Exp Immunol       Date:  1982-05       Impact factor: 4.330

7.  Mechanisms in removal of tumor by antibody.

Authors:  G T Stevenson; A J Bell; T R Evans; R R French; M J Glennie; T J Hamblin; K S Kan; G M Mead
Journal:  Cell Biophys       Date:  1994

8.  In vivo therapy of a murine B cell tumor (BCL1) using antibody-ricin A chain immunotoxins.

Authors:  K A Krolick; J W Uhr; S Slavin; E S Vitetta
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

9.  Mechanisms of tumour cell escape encountered in treating lymphocytic leukaemia with anti-idiotypic antibody.

Authors:  J Gordon; A K Abdul-Ahad; T J Hamblin; F K Stevenson; G T Stevenson
Journal:  Br J Cancer       Date:  1984-05       Impact factor: 7.640

10.  Therapy of murine leukemia with monoclonal antibody against a normal differentiation antigen.

Authors:  C C Badger; I D Bernstein
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.